1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Summary
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Quarterly Report Q3 2021: Oncoral – entering clinical collaboration

11/04/2021 | 02:01am EDT

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q3 2021 (July – September 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/

SIGNIFICANT EVENTS IN Q3 2021

  • Clinical collaboration agreement with Taiho Oncology Inc. for the development of Oncoral in combination with LONSURF®
  • Abstract for Orviglance® comparison study to gadolinium accepted as an oral paper presentation at the world’s largest radiology conference RSNA
  • FDA conditionally accepted Orviglance as the brand name for Mangoral
  • Guidance for expected recruitment completion to the SPARLE trial was extended to H1 2022 (previously H2 2021)

 
SIGNIFICANT EVENTS AFTER THE PERIOD

  • Food Effect Study with Orviglance successfully completed

 
FINANCIAL SUMMARY Q3 2021

  • Operating result of SEK -32.7M (SEK -16.3M)
  • Earnings per share of SEK -0.82 (SEK -0.51)
  • Cash flow from operations of SEK -30.7M (SEK -18.9M)
  • Cash and marketable securities of SEK 291.0M (SEK 220.7M)

 
“We are making steady progress across our clinical portfolio. Particularly, for our novel chemotherapy tablet Oncoral, we signed in September an important clinical collaboration agreement with Taiho Oncology. The collaboration concerns the upcoming global Phase 2 clinical study in gastric cancer with Oncoral in combination with Taiho Oncology’s LONSURF (trifluridine and tipiracil). The agreement shows the potential for Oncoral to be part of a new all-oral treatment regimen for gastric cancer.

We also continued the clinical development program and the commercial preparations for Orviglance, our diagnostic drug currently in Phase 3. The progress continued after the quarter when we completed our food effect study with Orviglance in October”, said Magnus Corfitzen, CEO at Ascelia Pharma.
 
A presentation for analysts, investors and media will be held today 4 November at 10:00am CET. The event will be hosted by the company’s CEO Magnus Corfitzen, CFO Kristian Borbos, CMO Carl Bjartmar and CCO Julie Waras Brogren. The presentation will be held in English. The presentation can be followed live via the link: https://tv.streamfabriken.com/ascelia-pharma-q3-2021

It will also be possible to take part of the audiocast afterwards at the same address or at Ascelia Pharma’s website: https://www.ascelia.com/ir-media/reports-presentations/ 

To participate in the telephone conference, please use the dial-in details shown below:
SE: +46 8 505 583 74
UK: +44 333 3009 035
US: +1 833 5268 396
DK: +45 354 455 77 (DK-PIN: 84534526#)

© Modular Finance, source Nordic Press Releases

All news about ASCELIA PHARMA AB (PUBL)
05/11TRANSCRIPT : Ascelia Pharma AB, Q1 2022 Earnings Call, May 11, 2022
CI
05/11QUARTERLY REPORT Q1 2022 : Strong Orviglance support from healthcare professionals
AQ
05/11Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/10Ascelia Pharma's Food Effect Study shows that Orviglance image enhancement of the liver..
AQ
05/10Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is N..
CI
05/05Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022
AQ
05/05Ascelia Pharma AB Announces Resignation of Bo Jesper Hansen as Board Member
CI
04/11Ascelia Pharma publishes Annual Report for 2021
AQ
04/05Notice of annual general meeting in ascelia pharma ab
AQ
04/01CFO Kristian Borbos to leave Ascelia Pharma
AQ
More news
Financials
Sales 2022 - - -
Net income 2022 -155 M -15,6 M -15,6 M
Net cash 2022 104 M 10,4 M 10,4 M
P/E ratio 2022 -4,57x
Yield 2022 -
Capitalization 692 M 69,4 M 69,4 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 21
Free-Float 83,7%
Chart ASCELIA PHARMA AB (PUBL)
Duration : Period :
Ascelia Pharma AB (publ) Technical Analysis Chart | ACE | SE0010573113 | MarketScreener
Technical analysis trends ASCELIA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 20,55 SEK
Average target price 61,50 SEK
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Magnus Olafsson Corfitzen Chief Executive Officer
Kristian Borbos Chief Financial Officer
Peter James Arthur Benson Chairman
Carl Bjartmar Chief Medical Officer
Bo Jesper Hansen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ASCELIA PHARMA AB (PUBL)-31.16%69
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567